Medicina (Kaunas, Lithuania)

Life (Basel, Switzerland)

jornal vascular brasileiro

World journal of urology

global spine journal

pharmaceutical medicine

[1] Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines.

[2] Evaluation of the Implementation of Additional Risk Minimization Activities in Europe, the USA, and Japan.

[3] therapeutic interchange of parenteral anticoagulants: challenges for pharmacy and therapeutics committees

[4] management of antithrombotic therapy during cardiac implantable device surgery

[5] direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats

[6] marine diterpenes: molecular modeling of thrombin inhibitors with potential biotechnological application as an antithrombotic

[7] evaluación del tripolifosfato de sodio como anticoagulante en determinaciones hematológicas en seres humanos assessment of anticoagulant sodium tripolyphosphate used in hematologic determinations in human being

[8] Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?

[9] Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review.

[10] Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.

[11] Thromboembolic, Bleeding, and Mortality Risks among Patients with Nonvalvular Atrial Fibrillation Treated with Dual Antiplatelet Therapy versus Oral Anticoagulants: A Population-Based Study.

[12] Non-vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter.

[13] Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies.

[14] Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.

[15] Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.

[16] How reliable is perioperative anticoagulant management? Determining guideline compliance and practice variation by a retrospective patient record review.

[17] Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.

[18] Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.

[19] Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients

[20] Corrigendum to “Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis” [Arch. Gerontol. Geriatr. 81 (March–April)(2019)209–214](S0167494318302450)(10.1016/j.archger.2018.12.013)

[21] Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis

[22] Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis

[23] Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis

[24] Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

[25] Economic evaluation of the use of non-Vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: A modelling analysis using the healthcare system in the Netherlands

[26] Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis

[27] Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis

[28] Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis

[29] Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis

[30] Comment on “Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis”

[31] Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

[32] Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials

[33] Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies

[34] Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis

[35] Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.

[36] Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

[37] Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants

[38] Synthesis, Antimicrobial, and Anticoagulant Activities of 2-(Arylsulfonyl)indane-1,3-diones

[39] Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants

[40] Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

[41] Low-Intensity Shockwave Therapy (LiST) for Erectile Dysfunction: Is It Safe for Patients on Anticoagulant Medication?

[42] Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America.

[43] Resistance to anticoagulant rodenticides in Martinique could lead to inefficient rodent control in a context of endemic leptospirosis.

[44] Development and Assessment of RecosDoc-MTeV to Improve the Quality of Direct Oral Anticoagulant Prescription for Venous Thromboembolic Disease.

[45] Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

[46] The perioperative management of direct oral anticoagulants, a single center observational study

[47] Direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.

[48] Perioperative antithrombotic (antiplatelet and anticoagulant) therapy in urological practice: a critical assessment and summary of the clinical practice guidelines.

[49] Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.

[50] Pharmacogenomics of 4-hydroxycoumarin anticoagulants

[51] Letter by Govindarajan and Salgado regarding article, "risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial"

[52] Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer.

[53] Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?

[54] Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?

[55] caracterizaÇÃo e atividade anticoagulante de polissacarÍdeos sulfatados extraÍdos da alga marrom dictyopteris justii

[56] indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients

[57] heterofucans from the brown seaweed canistrocarpus cervicornis with anticoagulant and antioxidant activities

[58] anticoagulante e opinião pessoal da autoridade: ambas, um risco certo versus um benefício incerto?

[59] therapeutic interchange of parenteral anticoagulants: challenges for pharmacy and therapeutics committees

[60] modern approaches to anticoagulant therapy during catheter ablation treatment of non-valvular atrial fibrillation

[61] heparina e k3edta como anticoagulantes para tambaqui (colossoma macropomum cuvier, 1816) heparin and k3edta as anticoagulants for tambaqui (colossoma macropomum cuvier, 1816)

[62] current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism

[63] newer anticoagulants and their impact on interventional pain procedures

[64] anticoagulant-induced hemopericardium with tamponade: a case report and review of the literature

[65] infartos cerebrais em pacientes jovens relacionados a deficiência de anticoagulantes naturais proteína c e proteína s protein c and s deficiencies related stroke in young patients

[66] non-vitamin k antagonist oral anticoagulants vs. warfarin at risk of fractures: a systematic review and meta-analysis of randomized controlled trials

[67] anticoagulant therapy in patients with non-valvular atrial fibrillation: drug choice and dosage adjustment

[68] hematoma subdural de medula espinhal associada ao uso de anticoagulante oral hematoma subdural de la médula espinal asociado al uso de anticoagulante oral spine subdural hematoma: a rare complication associated with vitamin k antagonist (vka)

[69] atrial sensor, remote monitoring and new anticoagulant drugs: identification and treatment of a patient with unknown and asymptomatic atrial flutter

[70] practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants

[71] the new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy

[72] terapia anticoagulante en fibrilación auricular

[73] non-traumatic intramural hematomas in patients on anticoagulant therapy: report of three cases and overview of the literature

[74] structural analysis and anticoagulant activities of the novel sulfated fucan possessing a regular well-defined repeating unit from sea cucumber

[75] evaluación del tripolifosfato de sodio como anticoagulante en determinaciones hematológicas en seres humanos assessment of anticoagulant sodium tripolyphosphate used in hematologic determinations in human being

[76] anticoagulant therapy in everyday clinical practice: data of the retrospective cross-sectional study

[77] use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence

[78] prevention of thromboembolic complications in atrial fibrillation - rat poison or new oral anticoagulants: do we have a choice, and should we be afraid to make it? first clinical experience with rivaroxaban in nizhny novgorod

[79] nonvitamin k antagonist oral anticoagulants (noacs): the tide continues to come in

[80] application of thrombin powder after tooth extraction in patients receiving anticoagulant therapy

[81] new anticoagulant strategies in st elevation myocardial infarction: trials and clinical implications

[82] cumarinas, interacción con anticoagulantes antagonistas de la vitamina k y seguridad del haba tonka coumarins: interaction with vitamin k antagonists and safety of tonka bean

[83] Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.

[84] [Efficiency of the Decision-Making Module in the Personalized Choice of an Anticoagulant].

[85] Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: a prospective study

[86] Antiplatelets and Anticoagulants in Vitreoretinal Surgery: A Systematic Review.